X

The Health Sciences Blog covers the latest trends and advances in life sciences and healthcare.

Prix Galien 2015 Re-Cap

Barbara Rudolph
Senior Content Marketing Manager

The progress of the
biopharmaceutical industry is roaring ahead at breakneck speed. There are more
than 7,000 medicines in development globally, up nearly 30 percent (%) from
just three years ago1, with
40 percent (%) of
these medicines-in-development having the potential to be Precision Medicine
(personalized) treatments1. The industry has created 3.4 million new
jobs, and R&D spending in 2014 was 10 percent (%) higher ($51.2 billion)
than just five years previously in 2009 ($46.4 billion) 1

Data, a
Bridge between Industries, a Vector towards Innovation

One of the root causes of this explosion of progress and momentum is a
data-centric partnership between the biopharmaceutical and technology
industries. More specifically, it’s the
meteoric advances in the technology industry’s ability to manage and analyze
the huge volumes of data created by biopharmaceutical and related health
industries. The momentum of therapeutic advances is increasing daily. Yet,
there is still much work to be done in facilitating stronger biopharma
–technology collaborations. 

The
Galien Forum

Last week, in line with its goal to serve as a catalyst for innovative
biotech – technology partnerships that that impact human health, the Galien Foundation
held its annual
Galien Forum and Prix  Galien2
Awards Dinner. These events brought
together leaders from
industry, academia, and government to discuss current pressing health
issues and recognize innovation that moves human health forward.

During the day-long Galien Forum, on a panel
discussing US Healthcare Reform, Jonathan Sheldon, Oracle Health Sciences VP, Product
Strategy, offered insightful opinions on how data driven intelligence could
support Precision Medicine initiatives and how data sharing could move
population health forward. Other Forum panels included discussions on:
Bioengineering for Better Health, autism, microbiota in human disease, the
promise of gene therapy, neurodegeneration, and the crisis of heart failure.

Panelists, to name a few, included a who’s who
of research and healthcare:

  • Bengt
    Samuelsson, Chair, MD, PhD, Nobel Laureate, Former President of Karolinska Institute
    and Former Chairman of the Nobel Foundation

  • Margaret Hamburg, former US commissioner of the FDA

  • Jeff Gordon,
    MD, Robert Glaser
    University. Professor & Director Genome Sciences and Systems Biology Center
    , Washington University

  • Roy Vagelos, Chair, MD, Chairman of Regeneron Pharmaceuticals and Retired Chairman
    and CEO, Merck

  • Richard
    Axel, Chair, MD, Nobel Laureate, Co-Director, the Kavli Institute for Brain
    Science, Columbia University 

  • Kenneth Frazier, President and CEO Merck

  • John W. Rowe, MD,
    Professor of Health Policy and Aging, Columbia University; and

  • Marc
    Tessier-Lavigne
    ,
    Chair, MD, PhD,
    President, Professor Laboratory of Brain Development and Repair, The
    Rockefeller University

All during the Forum, OHS offered
tweets and posts on panelists’ comments and opinions. In all, Oracle posted 23
messages on Facebook and 106 tweets throughout the day on Twitter.

Prix Galien Awards Dinner

The Prix Galien Awards Dinner took place at the venerable American
Museum of Natural History in Manhattan. The biotech star studded guest list enjoyed cocktails and hors
d’oeuvres in the Museum’s Grand Gallery and dinner in its Whale Room. During
the cocktail hour all 42 award nominees were photographed holding the Prix
Galien medal. (These were tweeted on Oracle Health Sciences CROAdvantage
Twitter Channel.)

During
his welcome address, Steve Rosenberg, Oracle Health Sciences SVP and GM,
offered informed comments, noting that
Oracle’s solutions contributed data driven intelligence to nine
out of ten of the Prix Galien award nominees. He also extended warm
congratulations to all the award nominees for their tremendous achievements. Also speaking at the dinner, Dr. William C. Campbell, 2015 Medicine Nobel Laureate, offered anecdotes in relation to his research, and Prix Galien Pro Bono Humanum Award Winner, Dr. Mary
Claire King,
provided keynote remarks on breakthroughs in
breast cancer.

The 2015 Prix Galien Award winners included:

  • Best
    Pharmaceutical Agent:
    Janssen
    Biotech & Pharmacyclics'
    Imbruvica, a new
    therapy for lymphocytic leukemia and mantle cell lymphoma.

  • Best Biotechnology Product: Bristol-Myers
    Squibb's

    Opdivo® and Merck's Keytruda®. Both products treat
    for melanoma or metastatic non-small lung cancer.

  • Best Medical Technology
    Product:
    T2
    Biosystems' T2Candida Panel,
    a diagnostic panel for the
    quick detection and monitoring of
    Candida infection and sepsis.

The Galien Forum and the Prix Galien Awards Dinner were not only a triumph for the Galien Foundation and Oracle Health Sciences, a Platinum Sponsor, but they were also a very enriching, educational experience for participants, panelists, and prize nominees, alike.

1 According
to PhRMA

2 The Prix Galien was
created in 1970. It was named in honor of Claudius Galenus (c. ~130–200 AD),
considered the father of medical science and modern pharmacology because he was
the first to use experiments to probe body functions. Worldwide, the Prix
Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical
research.








Be the first to comment

Comments ( 0 )
Please enter your name.Please provide a valid email address.Please enter a comment.CAPTCHA challenge response provided was incorrect. Please try again.Captcha
Oracle

Integrated Cloud Applications & Platform Services